Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Gurkan Guner1, Yasin Sezgin21Department of Medical Oncology, Van Training and Research Hospital, University of Health Sciences, Van, Türkiye, 2Division of Medical Oncology, Department of Internal Medicine, Van Yüzüncü Yıl University Faculty of Medicine, Van, Türkiye
Objectives: This study aimed to compare the efficacy of folinic acid plus 5-fluorouracil plus irinotecan (FOLFIRI), carboplatin plus paclitaxel, and cisplatin plus 5-FU regimens in second-line treatment of metastatic esophageal squamous cell cancer. Methods: The study included patients over the age of 18 with a diagnosis of esophageal squamous cell carcinoma, stage 4 disease, who had progressed after first-line chemotherapy treatment for metastatic disease and received a dual chemotherapy regimen as a second-line chemotherapy. Results: The mean age of 58 patients was 56.4±12.3 years and 33 (56.9%) of them were women. Among 58 patients, 18 received carboplatin plus paclitaxel, 25 received cisplatin plus 5-FU and 15 received FOLFIRI regimen. Second-line chemotherapy responses were 6.9% complete, 41.4% partial, 17.2% stable, and 34.5% of the patients developed progression. The median follow-up was 4.5 mo (0-46 mo). The median OS for all cohort was 14 mo (95% CI, 4.38-23.62) and there was no statistically difference between three groups (p=0.737). Conclusion: In our study, we observed that doublet chemotherapy regimens were effective in the second series treatment of metastatic squamous cell carcinoma and may be a good option for patients with good performance status and no access to immunotherapy. Keywords: Chemotherapy, esophageal squamous cell carcinoma, second-line treatment
Cite This Article
Guner G, Sezgin Y. Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma. EJMI. 2024; 8(1): 48-53
Corresponding Author: Gurkan Guner